Literatur
- 1
American Thoracic Society .
Standards for the diagnosis and care of patients with chronic
obstructive pulmonary disease.
Am J Respir Crit Care
Med.
1995;
152
S77-S120
- 2
Anthonisen N R, Manfreda J, Warren C P
W.
Antibiotic therapy in exacerbations of chronic obstructive
pulmonary disease.
Ann Intern
Med.
1987;
106
196-204
- 3
Ashutosh K, Sedat M, Fragale-Jackson J.
Effects of theophylline on respiratory drive in patients with
chronic obstructive pulmonary disease.
J Clin
Pharmacol.
1997;
37
1100-1107
- 4
Bach P B, Brown C, Gelfand S E, MacCrory D C.
Management of acute exacerbations of chronic obstructive
pulmonary disease: a summary and appraisal of published evidence.
Ann
Intern
Med.
2001;
134
600-620
- 5
Barbera J A, Roca J, Ferrer A. et al .
Mechanisms of worsening gas exchange during acute
exacerbations of chronic obstructive pulmonary disease.
Eur Respir
J.
1997;
10
1285-1291
- 6
Bardi G, Pierotello R, Desideri M, Valdisserri L, Bottai M, Palla A.
Nasal ventilation in COPD exacerbations: early and late
results of a prospective, controlled study.
Eur Respir J
.
2000;
15
98-104
- 7
Barnes P J.
Chronic obstructive pulmonary disease.
N Engl J
Med.
2000;
343
269-280
- 8
Barr R G, Rowe B H, Camargo C A.
Methyl-xanthines for exacerbations of chronic obstructive
pulmonary disease.
Cochrane Database Syst
Rev.
2001;
1
CD002168
- 9
Bhowmik A, Seemungal T A R, Sapsford R J, Wedzicha J A.
Relation of sputum inflammatory markers to symptoms and lung
function changes in COPD
exacerbations.
Thorax.
2000;
55
114-120
- 10
British Thoracic Society .
Guidelines for the management of chronic obstructive
pulmonary
disease.
Thorax.
1997;
52
S1-S28
- 11
British Thoracic Society Research Committee .
Oral N-Acetyl cysteine and exacerbation rates in patients
with chronic bronchitis and severe airways
obstruction.
Thorax.
1985;
40
832-835
- 12
Burge P S, Calverley P M A, Jones P W, Anderson J A, Maslen T K.
Randomised, double blind, placebo controlled study of
fluticasone propionate in patients with moderate to severe chronic obstructiv
pulmonary disease: the ISOLDE
trial.
BMJ.
2000;
320
1297-1303
- 13
Calverley P M
A, Pauwels R A, Vestbo J. et al .
Salmeterol/fluticasone propionate combination for one
year provides greater clinical benefit than its individual components in COPD
(abst).
Am J Respir Crit Care
Med.
2002;
165
A226
- 14
Casaburi R, Mahler D A, Jones P W. et al .
A long-term evaluation of once-daily inhaled tiotropium in
chronic obstructive pulmonary disease.
Eur Respir
J.
2002;
19
217-224
- 15 Celli B R, Benditt J, Albert R. Chronic obstructive pulmonary disease. London:
Mosby International Ltd In: Albert R, Spiro S, Jett J (Hrsg.):
Comprehensive respiratory
medicine 2000: 37.1-37.24
- 16
Chodosh S, McCarty J, Farkas S. et al. The Bronchitis Study Group .
Randomized, double-blind study of ciprofloxacin and
cefuroxime axetil for treatment of acute bacterial exacerbations of chronic
bronchitis.
Clin Infect
Dis.
1998;
27
722-729
- 17
Connors A F, Dawson N V, Tomas C, Harrell F E, Desbiens N, Fulkerson W J.
Outcomes following acute exacerbation of severe chronic
obstructive lung disease. The SUPPORT investigators (Study to Understand
Prognoses and Preferences for Outcomes and Risks of Treatments).
Am J
Respir Crit Care
Med.
1996;
154
959-967
- 18
Davies L, Angus R M, Calverley P M A.
Oral corticosteroids in patients admitted to hospital with
exacerbations of chronic obstructive pulmonary disease: a prospective
randomised controlled
trial.
Lancet.
1999;
354
456-460
- 19
Dewan N A, Rafique S, Kanwar B. et al .
Acute exacerbation of
COPD.
Chest.
2000;
117
662-671
- 20
Eller J, Ede A, Schaberg T, Niederman M S, Mauch H, Lode H.
Infective exazerbations of chronic obstructive pulmonary
disease. Relation between bacteriologic etiology and lung
function.
Chest.
1998;
113
1542-1548
- 21
Emerman C L, Lukens T W, Effron D.
Physician estimation of FEV1 in acute exacerbation
of
COPD.
Chest.
1994;
105
1709-1712
- 22
Fernandez A, Munoz J, de la Calle B. et al .
Comparison of one versus two bronchodilators in ventilated
COPD patients.
Intensive Care
Med.
1994;
20
199-202
- 23
Garcia-Aymerich J, Barreiro E, Farrero E, Marrades R M, Morera J, Anto J M.
Patients hospitalized for COPD have a high prevalence of
modificable risk factors for exacerbation (EFRAM study).
Eur Respir
J.
2000;
16
1037-1042
- 24
Garcia-Aymerich J, Monsó E, Marrades R M. et al .
Risk factors for hospitalization for a chronic obstructive
pulmonary disease exacerbation.
Am J Respir Crit Care
Med.
2001;
164
1002-1007
- 25 Gillissen A. Pathogenese der COPD. Bremen: Uni-Med
Verlag In: Gillissen A (Hrsg.): Die chronisch-obstruktive
Lungenerkrankung 2000: 46-67
- 26
Gompertz S, O’Brien C, Bayley D L, Hill S L, Stockley R A.
Changes in bronchial inflammation during acute exacerbations
of chronic bronchitis.
Eur Respir
J.
2001;
17
1112-1119
- 27
Jones S E, Packham S, Hebden M, Smith A P.
Domiciliary nocturnal intermittent positive pressure
ventilation in patients with respiratory failure due to severe COPD: long-term
follow up and effect on
survival.
Thorax.
1998;
53
495-498
- 28
Karg O, Bullemer F, Heindl S t.
Grenzen der nichtinvasiven Maskenbeatmung bei akuten
hpoxämischen
Gasaustauschstörungen.
Pneumologie.
1999;
53
S95-S97
- 29
Keenan S P, Gregor J, Sibbald W J, Coon M J, Gafni A.
Noninvasive positive pressure ventilation in the setting of
severe, acute exacerbations of chronic obstructive pulmonary disease: more
effective and less expensive.
Crit Care
Med.
2000;
28
2094-2102
- 30
Mahon J L, Laupacis A, Hodder R V. et al .
Theophylline for irreversible chronic airflow limitation: a
randomized study comparing n of 1 trials to standard
practice.
Chest.
1999;
115
38-48
- 31
Moayyedi P, Congleton J, Page R L, Pearson S B, Muers M F.
Comparison of nebulised salbutamol and ipratropium bromide
with salbutamol alone in the treatment of chronic obstructive pulmonary
disease.
Thorax.
1995;
50
834-837
- 32
Murata G H, Gorby M S, Kapsner C O, Chick T W, Halperin A K.
A multivariate model for prediction of relapse after
outpatient treatment of decompensated chronic obstructive pulmonary
disease.
Arch Intern
Med.
1992;
152
73-77
- 33
Nava S, Ambrosina N, Clini E. et al .
Noninvasive mechanical ventilation in the weaning of patients
with respiratory failure due to chronic obstructive pulmonary disease. A
randomized, controlled trial.
Ann Intern
Med.
1998;
128
721-728
- 34
Niewoehner D E, Erbland M L, Deupree R H. et al .
Effect of systemic glucocorticoids on exacerbations of
chronic obstructive pulmonary disease.
N Engl J
Med.
1999;
340
1941-1947
- 35
Paggiaro P L, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J.
Multicentre randomised placebo-controlled trial of inhaled
fluticasone propionate in patients with chronic obstructive pulmonary
disease.
Lancet.
1998;
351
773-780
- 36
Pauwels R A, Buist A S, Calverley P M A, Jenkins C, Hurd S S.
Global Strategy for the Diagnosis, Management, and Prevention
of Chronic Obstructive Pulmonary Disease.
Am J Respir Crit Care
Med.
2001;
163
1256-1276
- 37
Plant P K, Owen J L, Elliott M W.
Early use of non invasive ventilation (NIV) for acute
Exazerbations of COPD on general respiratory wards: a multicenter randomized
controlled
trial.
Lancet.
2000;
355
1931-1935
- 38
Politiek M J, Boorsma M, Aalbers R.
Comparison of formoterol, salbutamol and salmeterol in
methacholine-induced severe bronchoconstriction.
Eur Respir
J.
1999;
13
988-992
- 39
Poole P J, Veale P N.
The effect of sustained release morphine on breathlessness
and quality of life in severe chronic obstructive pulmonary
disease.
Am J Respir Crit Care
Med.
1998;
157
1877-1880
- 40
Rasmussen J B, Glennow C.
Reduction in days of illness after long term treatment with
N-acetyl cysteine controlled-release tablets in patients with chronic
bronchitis.
Eur J Respir
Dis.
1988;
1
351-355
- 41
Rodriguez-Roisin R.
Pulmonary gas exchange in acute respiratory
failure.
Eur J
Anaesthesiol.
1994;
11
5-13
- 42
Rodriguez-Roisin R.
Toward a consensus definition for COPD
exacerbations.
Chest.
2000;
117
398s-401s
- 43 Rodriguez-Roisin R, MacNee W. Pathophysiology of chronic obstructive pulmonary
disease. Sheffield: European Respiratory
Society In: Postma D S, Siafakas N M (Ed.): Management of
chronic obstructive pulmonary
disease 1998: 107-126
- 44
Rohde G, Wiethege A, Borg I. et al .
Respiratory viruses in exacerbations of chronic obstructive
pulmonary disease hospitalisation: a case-control
study.
Thorax.
2003;
58
37-42
- 45
Sachs A P, van der Waaij D, Groenier K H, Koeter G H, Schiphuis J.
Oropharyngeal flora in asthma and in chronic obstructive
pulmonary disease: indigenous oropharyngeal microorganisms in outpatients with
asthma or chronic obstructive pulmonary disease.
Am Rev Respir
Dis.
1993;
148
201-207
- 46
Saetta M, Di Stefano A, Turato G. et al .
CD8 T-lymphocytes in peripheral airways of smokers with
chronic obstructive pulmonary disease.
Am J Respir Crit Care
Med.
1998;
157
822-826
- 47
Schwartz J, Dockery D W.
Increased mortality in philadelphia with daily air pollution
concentrations.
Am Rev Respir
Dis.
1992;
145
600-604
- 48
Seemungal T A
R, Harper-Owen R, Bhowmik A, Jeffreis D J, Wedzicha J A.
Detection of rhinovirus in induced sputum at exacerbation of
chronic obstructive pulmonary disease.
Eur Respir
J.
2000;
16
677-683
- 49
Seemungal T A
R, Harper-Owen R, Bhowmik A. et al .
Respiratory viruses, symptoms, and inflammatory markers in
acute exacerbations and stable chronic obstructive pulmonary
disease.
Am J Respir Crit Care
Med.
2001;
164
1618-1623
- 50
Sethi S, Evans N, Grant B J B, Murphy T F.
New strains of bacteria and exacerbations of chronic
obstructive pulmonary disease.
N Engl J
Med.
2002;
347
465-471
- 51
Soler N, Torres A, Ewig S. et al .
Bronchial microbial patterns in severe exacerbations of
chronic obstructive pulmonary disease (COPD) requiring mechanical
ventilation.
Am J Respir Crit Care
Med.
1998;
157
1498-1505
- 52
Stockley R A, O’Brien C, Pye A, Hill S L.
Relationship of sputum color to nature and outpatient
management of acute exacerbations of
COPD.
Chest.
2000;
117
1638-1645
- 53
Szafranski W, Ramirez A, Menga G. et al .
Efficacy and safety of budesonide/formoterol in the
management of chronic obstructive pulmonary disease.
Eur Respir
J.
2003;
21
74-81
- 54
Téllez-Rojo M M, Fomieu I, Ruiz-Velasco S, Lezana M -A, Hernández-Avilla M -M.
Daily respiratory mortality and PM10 pollution in
Mexico City: importance of considering place of death.
Eur Respir
J.
2000;
16
391-396
- 55
Topeli A, Laghi F, Tobin M J.
The voluntary drive to breath is not decreased in hyperkapnic
patients with severe COPD.
Eur Respir
J.
2001;
18
53-60
- 56
Tsai T W, Gallagher E J, Lombardi G.
Guidelines for the selective ordering of admission chest
radiography in adult obstructive airway disease.
Ann Emerg
Med.
1993;
22
1854-1858
- 57
Turato G, Zuin R, Saetta M.
Pathogenesis and pathology of
COPD.
Respiration.
2001;
68
117-128
- 58
Vincken W, van Noord J A, Kesten S, Bantje Th A, Korducki L, Cornelissen P J G.
Improved health outcomes in patients with COPD during 1
yr’s treatment with tiotropium.
Eur Respir
J.
2002;
19
209-216
- 59
Voelkel N F, Tuder R.
COPD
exacerbation.
Chest.
2000;
117
376S-379S
- 60
Vogel F, Worth H, Adam D. et al .
Rationale Therapie bakterieller Atemwegsinfektionen.
Empfehlung der Paul-Ehrlich-Gesellschaft für Chemotherapie und der
Deutschen Atemwegsliga.
Chemotherapie
J.
2000;
9
3-23
- 61
Wollmer P, Ursing K, Midgren B, Eriksson L.
Inefficiency of chest percussion in the physical therapy of
chronic bronchitis.
Eur J Respir
Dis.
1985;
66
233-239
- 62
Worth H, Adam D, Handrick W. et al .
Prophylaxe und Therapie von bronchiale
Infektionen.
Med
Klin.
1997;
12
699-704
Prof. Dr. A. Gillissen
Robert Koch-Klinik, Klinikum „St. Georg”
Nikolai-Rumjanzew-Straße 100
04207 Leipzig
Phone: 0341/4231202
Fax: 0341/4231203
Email: adrian.gillissen@sanktgeorg.de
